Department of Production Platforms & Analytics, National Research Council Canada, Building Montreal, 6100 Avenue Royalmount, Montreal, QC H4P 2R2, Canada.
Department of Bioengineering, McGill University, Montreal, QC H3A 0E9, Canada.
Viruses. 2023 Oct 25;15(11):2152. doi: 10.3390/v15112152.
Adenoviruses are promising vectors for vaccine production and gene therapy. Despite all the efforts in removing animal-derived components such as fetal bovine serum (FBS) during the production of adenovirus vector (AdV), FBS is still frequently employed in the early stages of production. Conventionally, first-generation AdVs (E1 deleted) are generated in different variants of adherent HEK293 cells, and plaque purification (if needed) is performed in adherent cell lines in the presence of FBS. In this study, we generated an AdV stock in SF-BMAdR (A549 cells adapted to suspension culture in serum-free medium). We also developed a limiting dilution method using the same cell line to replace the plaque purification assay. By combining these two technologies, we were able to completely remove the need for FBS from the process of generating and producing AdVs. In addition, we demonstrated that the purified AdV stock is free of any replication-competent adenovirus (RCA). Furthermore, we demonstrated that our limiting dilution method could effectively rescue an AdV from a stock that is highly contaminated with RCA.
腺病毒是生产疫苗和基因治疗的有前途的载体。尽管在生产腺病毒载体(AdV)时,人们已经做出了各种努力来去除动物源性成分,如胎牛血清(FBS),但在生产的早期阶段,FBS 仍然经常被使用。传统上,第一代 AdV(E1 缺失)在不同的贴壁 HEK293 细胞变体中产生,如果需要,在存在 FBS 的情况下,在贴壁细胞系中进行噬斑纯化。在这项研究中,我们在 SF-BMAdR(适应无血清培养基悬浮培养的 A549 细胞)中生成了 AdV 库存。我们还使用相同的细胞系开发了一种有限稀释方法来替代噬斑纯化检测。通过结合这两种技术,我们能够完全去除生产和制备 AdV 过程中对 FBS 的需求。此外,我们证明了纯化的 AdV 库存不含任何具有复制能力的腺病毒(RCA)。此外,我们还证明了我们的有限稀释方法可以有效地从高度污染 RCA 的 AdV 库存中拯救出 AdV。